Drug Type Bispecific antibody |
Synonyms LQ 081, LQ081 |
Target |
Action inhibitors, antagonists |
Mechanism TL1A inhibitors(Tumor necrosis factor superfamily member 15 inhibitors), α4β7 antagonists(Integrin alpha-4/beta-7 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Crohn Disease | Preclinical | China | 01 May 2025 |






